Lucira Health, Inc. Form 8-K (April 13, 2021)

Summary

Current report on Form 8-K of Lucira Health, Inc. dated April 13, 2021, reporting under Item 2.02, Results of Operations and Financial Condition. The company states that on April 12, 2021 it issued a press release providing a business update and certain preliminary financial results for the first quarter ended March 31, 2021, furnished as Exhibit 99.1. The report states that the information is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. Item 9.01 lists Exhibit 99.1, the press release dated April 12, 2021, and the signature block is Erik T. Engelson, President and Chief Executive Officer, dated April 13, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" lhdx-8k_20210412.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 13, 2021

Lucira Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39976 | 27-2491037
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
1412 62nd Street Emeryville, California | 94608
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (510) 350-8071

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | LHDX | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b – 2 of the Securities Exchange Act of 1934 ( § 240.12b – 2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 12, 2021, Lucira Health, Inc. (the “Company”) issued a press release providing a business update and certain preliminary financial results for the first quarter ended March 31, 2021. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information contained herein and the accompanying exhibit are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description
99.1 | Press Release of Lucira Health, Inc., dated April 12, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lucira Health, Inc.
Date: April 13, 2021 | By: | /s/ Erik T. Engelson
Erik T. EngelsonPresident and Chief Executive Officer

File and source

File

SEC_LHDX_8-K_filed2021-04-13_0001564590-21-018734.htm

Size

36,790 bytes

SHA-256

ab0ec96980806cbacd4e8ab36a50881ea41068ffd1742afd3deafcdf5a2b6ef7

Our copy

SEC_LHDX_8-K_filed2021-04-13_0001564590-21-018734.htm

Original

www.sec.gov